X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
ChangeCipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
| CIPLA | GLENMARK PHARMA | CIPLA/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 43.6 | 13.6 | 319.6% | View Chart |
| P/BV | x | 3.6 | 3.8 | 94.0% | View Chart |
| Dividend Yield | % | 0.4 | 0.3 | 107.5% |
 CIPLA  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-17 |
GLENMARK PHARMA Mar-16 |
CIPLA/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 622 | 1,262 | 49.3% | |
| Low | Rs | 458 | 672 | 68.3% | |
| Sales per share (Unadj.) | Rs | 181.9 | 270.6 | 67.2% | |
| Earnings per share (Unadj.) | Rs | 12.9 | 24.9 | 51.7% | |
| Cash flow per share (Unadj.) | Rs | 29.3 | 34.4 | 85.2% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 100.0% | |
| Dividend yield (eoy) | % | 0.4 | 0.2 | 179.0% | |
| Book value per share (Unadj.) | Rs | 155.7 | 151.3 | 102.9% | |
| Shares outstanding (eoy) | m | 804.51 | 282.16 | 285.1% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 3.0 | 3.6 | 83.1% | |
| Avg P/E ratio | x | 42.0 | 38.9 | 108.0% | |
| P/CF ratio (eoy) | x | 18.4 | 28.1 | 65.6% | |
| Price / Book Value ratio | x | 3.5 | 6.4 | 54.3% | |
| Dividend payout | % | 15.5 | 8.0 | 193.3% | |
| Avg Mkt Cap | Rs m | 434,516 | 272,778 | 159.3% | |
| No. of employees | `000 | 23.0 | 10.0 | 229.9% | |
| Total wages/salary | Rs m | 26,338 | 13,782 | 191.1% | |
| Avg. sales/employee | Rs Th | 6,349.1 | 7,614.9 | 83.4% | |
| Avg. wages/employee | Rs Th | 1,143.0 | 1,374.8 | 83.1% | |
| Avg. net profit/employee | Rs Th | 449.3 | 700.2 | 64.2% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 146,302 | 76,340 | 191.6% | |
| Other income | Rs m | 2,287 | 356 | 642.0% | |
| Total revenues | Rs m | 148,589 | 76,696 | 193.7% | |
| Gross profit | Rs m | 24,758 | 14,172 | 174.7% | |
| Depreciation | Rs m | 13,229 | 2,691 | 491.5% | |
| Interest | Rs m | 1,594 | 1,789 | 89.1% | |
| Profit before tax | Rs m | 12,222 | 10,048 | 121.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -70 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,798 | 3,028 | 59.4% | |
| Profit after tax | Rs m | 10,354 | 7,019 | 147.5% | |
| Gross profit margin | % | 16.9 | 18.6 | 91.2% | |
| Effective tax rate | % | 14.7 | 30.1 | 48.8% | |
| Net profit margin | % | 7.1 | 9.2 | 77.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 87,370 | 59,096 | 147.8% | |
| Current liabilities | Rs m | 33,081 | 40,018 | 82.7% | |
| Net working cap to sales | % | 37.1 | 25.0 | 148.5% | |
| Current ratio | x | 2.6 | 1.5 | 178.8% | |
| Inventory Days | Days | 87 | 75 | 116.0% | |
| Debtors Days | Days | 62 | 119 | 52.3% | |
| Net fixed assets | Rs m | 111,567 | 39,075 | 285.5% | |
| Share capital | Rs m | 1,609 | 282 | 570.2% | |
| "Free" reserves | Rs m | 123,645 | 30,281 | 408.3% | |
| Net worth | Rs m | 125,254 | 42,703 | 293.3% | |
| Long term debt | Rs m | 36,454 | 24,873 | 146.6% | |
| Total assets | Rs m | 209,532 | 111,026 | 188.7% | |
| Interest coverage | x | 8.7 | 6.6 | 131.0% | |
| Debt to equity ratio | x | 0.3 | 0.6 | 50.0% | |
| Sales to assets ratio | x | 0.7 | 0.7 | 101.5% | |
| Return on assets | % | 5.7 | 7.9 | 71.9% | |
| Return on equity | % | 8.3 | 16.4 | 50.3% | |
| Return on capital | % | 8.5 | 17.5 | 48.5% | |
| Exports to sales | % | 34.2 | 43.3 | 79.0% | |
| Imports to sales | % | 8.3 | 7.4 | 112.3% | |
| Exports (fob) | Rs m | 50,050 | 33,044 | 151.5% | |
| Imports (cif) | Rs m | 12,203 | 5,672 | 215.1% | |
| Fx inflow | Rs m | 51,066 | 36,945 | 138.2% | |
| Fx outflow | Rs m | 17,678 | 61,066 | 28.9% | |
| Net fx | Rs m | 33,388 | -24,122 | -138.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 23,824 | 3,449 | 690.8% | |
| From Investments | Rs m | -13,127 | -8,802 | 149.1% | |
| From Financial Activity | Rs m | -13,239 | 6,986 | -189.5% | |
| Net Cashflow | Rs m | -2,478 | 934 | -265.4% | |
| Indian Promoters | % | 16.0 | 48.3 | 33.1% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 6.9 | 176.8% | |
| FIIs | % | 23.7 | 34.4 | 68.9% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 10.5 | 249.5% | |
| Shareholders | 161,166 | 56,727 | 284.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: STERLING BIOTECH SANOFI INDIA ALEMBIC PHARMA ORCHID PHARMA LTD NOVARTIS
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Base price erosion in the US and lower Zetia sales impacts profits.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
More Views on NewsA small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Most Indians who cannot find jobs, look at becoming self-employed.
The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Post demonetisation, a cut in bank savings deposits rates was in the offing.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
